Major Depressive Disorder Protocol

Mental HealthModerate Evidence

supplements

Primary

Supporting

Grade A

103

Studies

Primary Stack

Core supplements with strongest evidence

Omega-3 Fatty Acids (EPA-dominant)A

2-4g daily (minimum 60% EPA)

EPA reduces neuroinflammation and modulates serotonin/dopamine signaling

35 studies4,500 participants

Supporting Studies (1)

PMID: 30755416 - Omega-3 polyunsaturated fatty acids in depression meta-analysis (2019)

S-Adenosyl-L-Methionine (SAMe)A

800-1600mg daily

Methyl donor that supports neurotransmitter synthesis and methylation pathways

20 studies1,200 participants

Supporting Studies (1)

PMID: 28006325 - SAMe for depression systematic review (2016)

Supporting Stack

Additional supplements for enhanced results

Vitamin D3B

2000-4000 IU daily (target 40-60 ng/mL)

VDR in brain areas involved in mood; deficiency strongly associated with depression

↓Depression Symptoms↑Glycemic Control↑Insulin

18 studies2,400 participants

Methylfolate (5-MTHF)A

15mg daily

Active form of folate; essential for BH4 and monoamine neurotransmitter synthesis

8 studies520 participants

Supporting Studies (1)

PMID: 22691875 - L-methylfolate augmentation in depression (2012)

ZincB

25-30mg daily

Modulates NMDA receptors and BDNF; low levels correlate with treatment resistance

10 studies480 participants

Saffron (Crocus sativus)B

30mg daily (standardized extract)

Crocin and safranal modulate serotonin reuptake and have antioxidant effects

↓Blood glucose↑Hematocrit↑Hemoglobin↓Triglycerides↑Urea

12 studies650 participants

How This Protocol Works

Simple Explanation

Depression involves imbalances in neurotransmitters (serotonin, dopamine, norepinephrine), neuroinflammation, and reduced brain plasticity. This protocol addresses multiple underlying factors that contribute to depressive symptoms.

•EPA-dominant omega-3s have the strongest evidence for depression of any supplement. Meta-analyses show they're effective as monotherapy or augmentation. EPA specifically reduces brain inflammation and supports neurotransmitter function. Higher EPA ratios work better than DHA-dominant formulas.

•SAMe is a natural compound that the body uses to make neurotransmitters. Multiple studies show it works faster than conventional antidepressants (1-2 weeks vs 4-6 weeks) and can boost the effects of SSRIs.

•Vitamin D deficiency is remarkably common in depression. Vitamin D receptors are present throughout mood-regulating brain regions.

•Methylfolate (L-methylfolate) is the active form of folate that crosses the blood-brain barrier. It's essential for making serotonin, dopamine, and norepinephrine. About 30% of depressed patients have folate-related metabolic issues.

•Zinc deficiency is associated with treatment-resistant depression. It modulates brain plasticity through BDNF.

•Saffron has shown antidepressant effects comparable to fluoxetine in several studies.

Important: These supplements complement but don't replace professional treatment. Severe depression requires medical care.

Expected timeline: SAMe may work within 1-2 weeks; omega-3s and others take 4-8 weeks for full effect.

Clinical Perspective

Major depressive disorder involves monoamine deficiency, HPA axis dysregulation, neuroinflammation, reduced BDNF/neuroplasticity, and aberrant glutamate signaling. This protocol addresses multiple pathways.

•Omega-3 EPA (A-grade): Meta-analysis (PMID: 30755416) of 26 RCTs: significant antidepressant effect (SMD = 0.50). EPA>60% formulations outperform DHA-dominant. Mechanisms: reduces PGE2, IL-6, TNF-α; modulates membrane fluidity affecting 5-HT1A signaling.

•SAMe (A-grade): Methyl donor for catechol-O-methyltransferase and serotonin/dopamine synthesis. Meta-analysis (PMID: 28006325): effective as monotherapy and augmentation. Faster onset than SSRIs. Caution: can trigger mania in bipolar disorder.

•Vitamin D3 (B-grade): VDR in prefrontal cortex, hippocampus, hypothalamus. Regulates tyrosine hydroxylase (DA synthesis) and tryptophan hydroxylase (5-HT synthesis). Meta-analyses show benefit when 25-OH-D <20 ng/mL at baseline.

•L-Methylfolate (A-grade): Active folate crosses BBB. Essential for BH4 regeneration (cofactor for monoamine synthesis). STAR*D adjunct study and controlled trials (PMID: 22691875) show 15mg augments SSRI response. Particularly beneficial with MTHFR variants.

•Zinc (B-grade): Modulates NMDA receptor, increases BDNF, inhibits glutamate release. Serum zinc inversely correlates with depression severity. Meta-analysis supports adjunctive use.

•Saffron (B-grade): Crocin inhibits serotonin reuptake; safranal modulates GABA-A. Multiple RCTs show equivalence to fluoxetine/imipramine. Dose: 30mg standardized extract.

Protocol stratification:

•Inflammatory phenotype (elevated CRP): prioritize EPA, curcumin

•Treatment-resistant: add methylfolate, zinc

•Low energy/anhedonia: consider SAMe, tyrosine

Monitoring: PHQ-9, HAM-D. Check 25-OH-D, RBC folate, zinc levels.

Safety: SAMe contraindicated in bipolar disorder. Monitor for serotonin syndrome if combining with SSRIs.

View All Protocols